SB 318

Drug Profile

SB 318

Alternative Names: SB-318

Latest Information Update: 17 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sangamo Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; TTK protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis I
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis I

Most Recent Events

  • 13 Jul 2017 SB 318 receives Fast Track designation for Mucopolysaccharidosis I [IV,Infusion] in USA
  • 27 Feb 2017 Sangamo Therapeutics receives Rare Pediatric Disease Designation for Mucopolysaccharidosis Type I
  • 08 Feb 2017 Phase-I/II clinical trials in Mucopolysaccharidosis I in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top